{
    "hands_on_practices": [
        {
            "introduction": "The credibility of a noninferiority trial hinges on the noninferiority margin, $\\Delta$. This margin is not an arbitrary value but must be rigorously derived to ensure that a \"noninferior\" drug is still meaningfully effective. This exercise guides you through the foundational process of setting $\\Delta$ by synthesizing historical data and applying principled constraints, a critical skill for designing scientifically and ethically sound clinical trials. ",
            "id": "4600763",
            "problem": "A new antihypertensive test drug is planned to be evaluated in a noninferiority randomized clinical trial against an established active control, where a placebo arm is ethically infeasible. The noninferiority margin $\\Delta$ must be set to preserve a clinically meaningful fraction of the active control’s historical effect relative to placebo. Consider the following historical evidence from two independent, high-quality randomized controlled trials of the active control versus placebo, each measuring mean change in systolic blood pressure (SBP) at $8$ weeks:\n\n- Trial $1$: mean difference (active minus placebo) $=10$ $\\mathrm{mmHg}$, with reported standard error $2$ $\\mathrm{mmHg}$.\n- Trial $2$: mean difference (active minus placebo) $=14$ $\\mathrm{mmHg}$, with reported standard error $3$ $\\mathrm{mmHg}$.\n\nAssume independence across trials and adopt the usual normal sampling model for trial-level effect estimates. Define the historical effect $\\theta_{H}$ as the common mean difference (active control minus placebo) across trials under a fixed-effect constancy assumption, and use a conservative estimate for $\\theta_{H}$ given by the lower bound of a two-sided $95\\%$ confidence interval (CI) for the pooled fixed-effect estimate.\n\nStarting from the foundational definitions of noninferiority and the requirement to preserve a fraction $f$ of the active control’s historical effect relative to placebo, derive the relationship $\\Delta=f\\,\\theta_{H}$. Then, justify a principled choice of $f$ based on clinical pharmacology considerations by simultaneously enforcing:\n- that $\\Delta$ does not exceed the Minimal Clinically Important Difference (MCID) for SBP, taken here as $5$ $\\mathrm{mmHg}$, and\n- that at least half of the conservative historical effect is preserved to guard against loss of assay sensitivity and violations of constancy.\n\nCompute the resulting noninferiority margin $\\Delta$ implied by these principles using the data above. Express the final margin in $\\mathrm{mmHg}$ and round your answer to four significant figures.",
            "solution": "The problem statement is assessed to be valid. It is scientifically grounded in the principles of clinical trial design and biostatistics, specifically the methodology for establishing a noninferiority margin. The problem is well-posed, providing all necessary data and a clear set of constraints and objectives. The terminology is objective and formal. Therefore, a full solution is warranted.\n\nThe solution will be structured in five parts:\n1.  Derivation and interpretation of the relationship between the noninferiority margin $\\Delta$ and the historical effect $\\theta_H$.\n2.  Calculation of the pooled historical effect estimate via fixed-effect meta-analysis.\n3.  Determination of the conservative historical effect, $\\theta_H$.\n4.  Application of the principled constraints to determine the final margin, $\\Delta$.\n5.  Final numerical computation and rounding.\n\n**1. Foundational Basis for the Noninferiority Margin**\n\nIn a noninferiority trial, the objective is to demonstrate that a new test drug (T) is not unacceptably worse than an established active control (A). The difference in their true mean effects is denoted $\\mu_T - \\mu_A$. Noninferiority is declared if we can be confident that this difference is greater than some negative margin, $-\\Delta$, where $\\Delta > 0$. That is, we wish to show $\\mu_T - \\mu_A > -\\Delta$, which is equivalent to showing that the loss of effect, $\\mu_A - \\mu_T$, is less than the margin $\\Delta$.\n\nThe margin $\\Delta$ must be chosen such that a drug satisfying this criterion still has a clinically meaningful effect. When a placebo arm is unethical, this is established by referencing historical data on the active control's effect versus placebo (P), denoted $\\theta_H = \\mu_A - \\mu_P$. We must ensure that $\\Delta$ is smaller than $\\theta_H$; otherwise, a \"noninferior\" drug could be no better than placebo.\n\nThe problem requires deriving the relationship $\\Delta = f\\,\\theta_H$. This relationship formalizes the margin $\\Delta$ as a pre-specified fraction $f$ of the historical effect $\\theta_H$. This fraction $f$ represents the maximum proportion of the active control's effect that we are willing to lose in the test drug.\n\nIf a trial successfully demonstrates that $\\mu_A - \\mu_T  \\Delta$, and we substitute $\\Delta = f\\,\\theta_H$, we have $\\mu_A - \\mu_T  f\\,\\theta_H$. The effect of the test drug relative to placebo can be expressed as:\n$$ \\mu_T - \\mu_P = (\\mu_T - \\mu_A) + (\\mu_A - \\mu_P) = -(\\mu_A - \\mu_T) + \\theta_H $$\nUsing the noninferiority result, $-(\\mu_A - \\mu_T) > -f\\,\\theta_H$. Substituting this into the previous equation gives:\n$$ \\mu_T - \\mu_P > -f\\,\\theta_H + \\theta_H = (1 - f)\\theta_H $$\nThis shows that if noninferiority is established with a margin $\\Delta = f\\,\\theta_H$, the test drug is guaranteed to preserve at least a fraction $(1-f)$ of the active control's historical effect relative to placebo.\n\n**2. Pooled Estimate of the Historical Effect**\n\nWe perform a fixed-effect meta-analysis to combine the results from the two historical trials. Let the effect estimates be $\\hat{\\theta}_1$ and $\\hat{\\theta}_2$, with standard errors $s_1$ and $s_2$.\nGiven data:\n- Trial 1: $\\hat{\\theta}_1 = 10 \\, \\mathrm{mmHg}$, $s_1 = 2 \\, \\mathrm{mmHg}$\n- Trial 2: $\\hat{\\theta}_2 = 14 \\, \\mathrm{mmHg}$, $s_2 = 3 \\, \\mathrm{mmHg}$\n\nThe weight for each study $i$ is the inverse of its variance, $w_i = 1/s_i^2$.\n$$ w_1 = \\frac{1}{s_1^2} = \\frac{1}{2^2} = \\frac{1}{4} $$\n$$ w_2 = \\frac{1}{s_2^2} = \\frac{1}{3^2} = \\frac{1}{9} $$\nThe pooled effect estimate, $\\hat{\\theta}_{\\text{pool}}$, is the weighted average of the individual estimates:\n$$ \\hat{\\theta}_{\\text{pool}} = \\frac{w_1 \\hat{\\theta}_1 + w_2 \\hat{\\theta}_2}{w_1 + w_2} = \\frac{(\\frac{1}{4})(10) + (\\frac{1}{9})(14)}{\\frac{1}{4} + \\frac{1}{9}} = \\frac{\\frac{10}{4} + \\frac{14}{9}}{\\frac{9+4}{36}} = \\frac{\\frac{90+56}{36}}{\\frac{13}{36}} = \\frac{146}{13} \\, \\mathrm{mmHg} $$\nThe variance of the pooled estimate is the reciprocal of the sum of the weights:\n$$ \\mathrm{Var}(\\hat{\\theta}_{\\text{pool}}) = \\frac{1}{w_1 + w_2} = \\frac{1}{\\frac{1}{4} + \\frac{1}{9}} = \\frac{1}{\\frac{13}{36}} = \\frac{36}{13} \\, \\mathrm{mmHg}^2 $$\nThe standard error of the pooled estimate is the square root of the variance:\n$$ \\mathrm{SE}(\\hat{\\theta}_{\\text{pool}}) = \\sqrt{\\frac{36}{13}} = \\frac{6}{\\sqrt{13}} \\, \\mathrm{mmHg} $$\n\n**3. Conservative Estimate of the Historical Effect ($\\theta_H$)**\n\nThe problem specifies using a conservative estimate for the historical effect, defined as the lower bound of a two-sided $95\\%$ confidence interval (CI) for the pooled estimate. A two-sided $(1-\\alpha)$ CI is given by $\\hat{\\theta}_{\\text{pool}} \\pm z_{1-\\alpha/2} \\mathrm{SE}(\\hat{\\theta}_{\\text{pool}})$. For a $95\\%$ CI, $\\alpha=0.05$, and the critical value from the standard normal distribution is $z_{0.975} = 1.96$.\n\nThe conservative historical effect $\\theta_H$ is therefore:\n$$ \\theta_H = \\hat{\\theta}_{\\text{pool}} - z_{0.975} \\mathrm{SE}(\\hat{\\theta}_{\\text{pool}}) $$\n$$ \\theta_H = \\frac{146}{13} - 1.96 \\left(\\frac{6}{\\sqrt{13}}\\right) \\, \\mathrm{mmHg} $$\n\n**4. Application of Principled Constraints**\n\nThe choice of the noninferiority margin $\\Delta$ must satisfy two simultaneous conditions:\n1.  $\\Delta$ must not exceed the Minimal Clinically Important Difference (MCID).\n    $$ \\Delta \\le 5 \\, \\mathrm{mmHg} $$\n2.  At least half of the conservative historical effect $\\theta_H$ must be preserved. As derived in Part 1, the fraction of preserved effect is $(1-f)$. So, this condition is $(1-f) \\ge 0.5$, which implies $f \\le 0.5$. Using the relationship $\\Delta = f\\,\\theta_H$, this translates to a constraint on $\\Delta$:\n    $$ \\frac{\\Delta}{\\theta_H} \\le 0.5 \\implies \\Delta \\le 0.5\\,\\theta_H $$\n\nTo satisfy both constraints, $\\Delta$ must be less than or equal to the more restrictive (smaller) of the two upper bounds. A principled choice for the margin is the largest value that adheres to all constraints, as this minimizes the required sample size for the new trial.\n$$ \\Delta = \\min(5 \\, \\mathrm{mmHg}, \\, 0.5\\,\\theta_H) $$\n\n**5. Final Calculation**\n\nFirst, we compute the numerical value for $\\theta_H$:\n$$ \\theta_H = \\frac{146}{13} - \\frac{1.96 \\times 6}{\\sqrt{13}} \\approx 11.230769 - \\frac{11.76}{3.605551} \\approx 11.230769 - 3.261637 \\approx 7.969132 \\, \\mathrm{mmHg} $$\nNext, we compute the second upper bound for $\\Delta$:\n$$ 0.5\\,\\theta_H \\approx 0.5 \\times 7.969132 \\approx 3.984566 \\, \\mathrm{mmHg} $$\nNow we determine $\\Delta$ by taking the minimum of the two bounds:\n$$ \\Delta = \\min(5, \\, 3.984566) = 3.984566 \\, \\mathrm{mmHg} $$\nThe problem requires rounding the final answer to four significant figures.\n$$ \\Delta \\approx 3.985 \\, \\mathrm{mmHg} $$\nThis value is the appropriate noninferiority margin. It is smaller than the MCID of $5 \\, \\mathrm{mmHg}$ and ensures that the new drug, if proven noninferior, will preserve at least $50\\%$ of the active control's conservatively estimated historical effect.",
            "answer": "$$\\boxed{3.985}$$"
        },
        {
            "introduction": "In the analysis of clinical trials, theoretical ideals meet real-world complexities like patient nonadherence. This practice explores the critical distinction between Intention-to-Treat (ITT) and Per-Protocol (PP) analysis, demonstrating how nonadherence can introduce a bias that misleadingly favors a noninferiority conclusion. By working through a quantitative example, you will understand why regulatory bodies insist on a dual-analysis strategy to ensure the integrity of the trial's findings. ",
            "id": "4600801",
            "problem": "A sponsor plans an active-controlled noninferiority trial of a new antibiotic versus a standard-of-care antibiotic for hospital-acquired bacterial pneumonia, with the primary endpoint defined as all-cause mortality by day $28$. The trial cannot ethically include a placebo arm, so assay sensitivity must be established by design and analysis, including consistency with historical placebo-controlled evidence about the active control’s benefit. The noninferiority margin on the risk-difference scale is prespecified as $\\Delta = 0.05$, where lower risk is better and noninferiority is concluded if the risk difference $p_{\\text{new}} - p_{\\text{active}}  \\Delta$ is supported by a confidence interval excluding $\\Delta$ in the unfavorable direction.\n\nSuppose the following are true in the source population under full adherence to assigned therapy: the event risk with the active control is $p_{\\text{active,on}} = 0.10$ and with the new antibiotic is $p_{\\text{new,on}} = 0.17$, so the true on-treatment risk difference is $0.07$. Also suppose that in the planned trial, nonadherence (treatment discontinuation or cross-over) occurs symmetrically at rate $q = 0.30$ in each arm, and that among nonadherent participants the event risk is $p_{\\text{off}} = 0.25$ regardless of original assignment. Investigators will perform both an Intention-to-Treat (ITT; analyze as randomized) analysis and a Per-Protocol (PP; analyze adherent participants without major deviations) analysis. Confidence intervals will be two-sided $95\\%$ intervals based on large-sample methods.\n\nUsing only fundamental definitions of ITT and PP estimands, the law of total probability for mixture populations, and the standard noninferiority hypothesis structure relative to $\\Delta$, reason about how nonadherence affects the estimand in each analysis set and the direction of bias relative to the true on-treatment effect. Then, determine which option below best states:\n\n- the direction of bias of ITT versus PP in noninferiority trials with active controls when nonadherence dilutes treatment effects,\n- a quantitative consequence in the scenario above sufficient to see the risk of a false noninferiority conclusion under ITT, and\n- a scientifically justified, prespecified dual-analysis strategy with clear reconciliation rules that preserves assay sensitivity and controls false noninferiority risk.\n\nChoose the single best option.\n\nA. In noninferiority trials, ITT tends to bias toward noninferiority when nonadherence dilutes between-group differences, whereas PP mitigates this dilution and is typically more conservative for noninferiority. In the scenario, the ITT risk difference is attenuated toward $0$, approximately below $\\Delta$ (about $0.049$), risking a false noninferiority conclusion, while a PP analysis approximates the true on-treatment difference near $0.07$ and would not support noninferiority. Therefore, prespecify dual primary analyses (modified ITT and PP) and declare noninferiority only if both analyses’ two-sided $95\\%$ confidence interval upper bounds for $p_{\\text{new}} - p_{\\text{active}}$ are $ \\Delta$, with prespecified handling of missing data, adherence definitions and windows, and consistency checks to support assay sensitivity relative to historical placebo-controlled effects.\n\nB. In noninferiority trials, ITT is conservative because it maximizes between-group differences under nonadherence, while PP is anti-conservative. In the scenario, the ITT risk difference would increase above $0.07$, so noninferiority should be declared if either ITT or PP meets $\\Delta$ to preserve power, with reconciliation only if the two estimates differ by more than $10\\%$.\n\nC. PP is essentially unbiased because it excludes protocol deviations; ITT is biased and should be avoided in noninferiority. In the scenario, PP would exactly recover the true difference of $0.07$, so only PP should drive the primary noninferiority claim, and no reconciliation with ITT is necessary.\n\nD. Nonadherence symmetrically affects both arms, so neither ITT nor PP is biased for noninferiority. In the scenario, the ITT and PP differences are the same, so any analysis that yields a two-sided $95\\%$ confidence interval overlapping $\\Delta$ on either side can be declared noninferior if the point estimate is $ \\Delta$, and reconciliation rules are unnecessary because the estimands coincide.",
            "solution": "The problem asks for an analysis of a noninferiority trial scenario to understand the impact of nonadherence on Intention-to-Treat (ITT) and Per-Protocol (PP) analyses and to identify the correct inferential strategy.\n\n**1. Calculate the True and Observed Effects**\n\nFirst, let's establish the ground truth. The true on-treatment risk difference is $p_{\\text{new,on}} - p_{\\text{active,on}} = 0.17 - 0.10 = 0.07$. The noninferiority margin is $\\Delta = 0.05$. Since the true difference ($0.07$) is greater than the margin ($0.05$), the new drug is truly inferior, and a correct analysis should not conclude noninferiority.\n\nNext, we calculate the expected risk difference under the ITT principle, which analyzes all patients as randomized. The risk in each arm becomes a weighted average of adherent and nonadherent subjects.\n-   Proportion adherent: $1 - q = 1 - 0.30 = 0.70$\n-   Proportion nonadherent: $q = 0.30$\n\nThe ITT risk for the new drug is: $p_{\\text{new, ITT}} = (0.70 \\times p_{\\text{new,on}}) + (0.30 \\times p_{\\text{off}}) = (0.70 \\times 0.17) + (0.30 \\times 0.25) = 0.119 + 0.075 = 0.194$.\nThe ITT risk for the active control is: $p_{\\text{active, ITT}} = (0.70 \\times p_{\\text{active,on}}) + (0.30 \\times p_{\\text{off}}) = (0.70 \\times 0.10) + (0.30 \\times 0.25) = 0.070 + 0.075 = 0.145$.\n\nThe ITT risk difference is $p_{\\text{new, ITT}} - p_{\\text{active, ITT}} = 0.194 - 0.145 = 0.049$.\n\n**2. Analyze the Bias and Consequences**\n\n-   **PP Analysis:** A Per-Protocol analysis, by definition, considers only adherent subjects. The risk difference it estimates is the on-treatment difference of $0.07$. Since $0.07 > \\Delta$, this analysis would correctly point toward failing to show noninferiority.\n-   **ITT Analysis:** The ITT analysis yields a risk difference of $0.049$. Since $0.049  \\Delta$, this analysis would incorrectly suggest that the noninferiority criterion is met, leading to a false conclusion.\n\nThe nonadherence (where outcomes for nonadherent subjects are the same in both arms) has diluted the true difference of $0.07$ toward the null value of $0$, resulting in an observed difference of $0.049$. In a superiority trial, this bias toward the null is \"conservative\" (makes it harder to prove a drug works). However, in a noninferiority trial, this same bias is \"anti-conservative\" because it makes it easier to meet the noninferiority criterion, increasing the risk of wrongly declaring an inferior drug as noninferior.\n\n**3. Evaluate the Options**\n\n-   **Option A** correctly identifies that ITT biases toward noninferiority in this setting. It correctly calculates the ITT difference as approximately $0.049$, which is less than $\\Delta=0.05$, and notes this risks a false conclusion. It also correctly states that the PP analysis would approximate the true difference ($0.07$) and not support noninferiority. Finally, it proposes the standard, accepted regulatory strategy: prespecify both ITT and PP analyses and require the noninferiority criterion to be met in both to ensure a robust conclusion. This is the correct approach.\n-   **Option B** incorrectly describes the direction of bias. ITT dilutes, not maximizes, differences here. Proposing that noninferiority can be declared if *either* analysis passes is a flawed strategy that inflates the chance of a false positive.\n-   **Option C** is incorrect because while a PP analysis avoids the dilution from nonadherence, it is highly susceptible to selection bias from excluding patients post-randomization, so it is not \"essentially unbiased.\" Relying solely on PP is not best practice.\n-   **Option D** is incorrect because, as calculated, nonadherence does cause a bias in the ITT estimand, and the ITT and PP differences are not the same ($0.049$ vs. $0.07$).\n\nTherefore, Option A provides the most accurate analysis of the situation and proposes the most scientifically sound strategy.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A conclusion of noninferiority from a primary analysis is only the beginning of the scientific inquiry. Because these trials often rely on untestable assumptions, such as the constancy of an active control's effect over time, a rigorous evaluation of the result's robustness is paramount. This exercise challenges you to develop a comprehensive sensitivity analysis plan, stress-testing a noninferiority finding against plausible biases from missing data, protocol deviations, and violations of the constancy assumption. ",
            "id": "4600788",
            "problem": "A noninferiority trial in clinical pharmacology compares a new therapy $T$ to an established active control $C$ on a binary adverse outcome at $12$ weeks. There is no placebo arm in the current study. Historical placebo-controlled evidence for $C$ is available from a high-quality meta-analysis. The core definitions and assumptions are as follows:\n\n- Noninferiority is assessed by requiring the upper bound of a two-sided $95\\%$ confidence interval (CI) for the risk difference $RD_{T,C} = p_T - p_C$ to be strictly below a prespecified noninferiority margin $\\Delta$ on the same scale.\n- The preservation-of-effect approach sets $\\Delta$ by maintaining a fraction $f$ of the historical active control benefit versus placebo under the constancy assumption that the effect of $C$ versus placebo in the current setting is similar to that observed historically.\n- The constancy assumption may be violated if background care or patient characteristics differ in ways that diminish the effect of $C$ versus placebo in the current trial; sensitivity analyses should evaluate robustness to such violations.\n- Missing outcomes and post-randomization biases (for example, differential adherence or rescue medication) can favor $T$; sensitivity analyses should stress-test conclusions under plausible bias magnitudes and worst-case missingness.\n\nData and design specifics:\n\n- Historical meta-analysis of $C$ versus placebo on the absolute risk difference scale yields a pooled $RD_{C,P} = -0.12$ with a two-sided $95\\%$ CI of $\\left[-0.16,-0.08\\right]$. A preservation fraction $f = 0.5$ was prespecified, and the initial noninferiority margin was set on the absolute scale at $\\Delta = 0.04$.\n- In the current trial, $n_T = n_C = 3000$, with observed event risks $p_T = 0.212$ and $p_C = 0.200$. The estimated $RD_{T,C} = 0.012$ with a two-sided $95\\%$ CI of $\\left[-0.009,0.033\\right]$, so the noninferiority criterion is met versus $\\Delta = 0.04$.\n- Missing outcome proportions are $4\\%$ in $T$ and $3\\%$ in $C$. There is concern that post-randomization factors (for example, differential adherence) could confer a net favorable bias to $T$ as large as $b = 0.01$ (absolute risk), with $b = 0.005$ also considered plausible.\n- Clinicians posit plausible constancy violations such that the absolute benefit of $C$ versus placebo in the current setting could be attenuated by $25\\%$ to $50\\%$ relative to the historical evidence.\n\nWhich of the following sensitivity analysis plans most appropriately and rigorously tests the robustness of the noninferiority conclusion to plausible violations of constancy, including worst-case and bias-adjusted scenarios, while adhering to the prespecified absolute risk difference scale?\n\nA. Recompute noninferiority margins on the absolute risk difference scale by degrading the historical $RD_{C,P}$ lower $95\\%$ bound in magnitude by $25\\%$ and $50\\%$ and applying the prespecified preservation fraction $f = 0.5$, yielding attenuated margins $\\Delta_{25\\%}$ and $\\Delta_{50\\%}$. Compare the observed upper $95\\%$ CI bound of $RD_{T,C}$ to $\\Delta$, $\\Delta_{25\\%}$, and $\\Delta_{50\\%}$. Implement bias-adjusted analyses by shifting the point estimate and CI for $RD_{T,C}$ upward by $b \\in \\{0.005,0.01\\}$ to reflect net favorable bias to $T$ and reassess noninferiority. Conduct a worst-case missing-data analysis by imputing all missing outcomes in $T$ as events and all missing in $C$ as non-events to re-estimate $RD_{T,C}$ and its CI, and complement with a tipping-point analysis over a grid of outcome probabilities for missingness. As a cross-check on the constancy anchor, repeat the margin recalculation and decision rule on the log risk ratio scale using the historical $RR_{C,P}$ lower bound, verifying consistency of conclusions across scales.\n\nB. Switch the analysis to an odds ratio noninferiority margin derived post hoc from the historical risk differences; use a per-protocol population only; impute missing data by last observation carried forward; and ignore uncertainty in the historical evidence by using the historical point estimate to set the margin.\n\nC. Use a two-sided superiority test of $T$ versus $C$ at $\\alpha = 0.05$ as the primary robustness check; handle missing data only with multiple imputation under missing-at-random assumptions; and maintain the original $\\Delta = 0.04$ without modification for potential constancy violations.\n\nD. Discard the historical meta-analysis and, post hoc, identify a contemporary external placebo cohort to re-estimate the margin and reinterpret the trial as a superiority study versus placebo, thereby bypassing sensitivity analyses within the noninferiority framework.\n\nSelect the single best option.",
            "solution": "The problem asks us to evaluate four proposed sensitivity analysis plans for a noninferiority trial whose primary analysis has concluded noninferiority. A rigorous sensitivity analysis is crucial for noninferiority claims because they often rest on assumptions that cannot be directly tested in the trial itself, such as the constancy assumption. The goal is to stress-test the conclusion against plausible deviations from these assumptions. Let's evaluate each option against the principles of robust sensitivity analysis.\n\nThe primary conclusion of noninferiority is based on the upper bound of the $95\\%$ CI for the risk difference, $RD_{T,C}$, being $0.033$, which is below the prespecified margin $\\Delta = 0.04$. The key challenges to this conclusion are: (1) potential violation of the constancy assumption, (2) post-randomization biases favoring therapy $T$, and (3) missing data. A good sensitivity analysis plan must address all three.\n\n**Option A** proposes a comprehensive, multi-faceted plan:\n1.  **Constancy Assumption:** It suggests re-calculating the noninferiority margin $\\Delta$ by assuming the historical effect of the control is attenuated. The historical risk reduction of control $C$ vs. placebo $P$ is at least $8\\%$ (based on the conservative lower bound of the historical effect CI, corresponding to $RD_{C,P} = -0.08$). Attenuating this effect by $25\\%$ would give a new effective risk reduction of $0.08 \\times (1-0.25) = 0.06$. The new margin would be $\\Delta' = f \\times 0.06 = 0.5 \\times 0.06 = 0.03$. Since the observed upper CI bound of $0.033$ is greater than this new, stricter margin, the noninferiority conclusion would be challenged. This is a standard and appropriate way to test robustness to constancy violations.\n2.  **Post-randomization Bias:** It suggests adding plausible bias amounts ($b=0.005$ and $b=0.01$) to the observed point estimate and its CI. For a bias of $b=0.01$ favoring $T$, the adjusted upper CI bound would be $0.033 + 0.01 = 0.043$. Since this exceeds the original margin $\\Delta=0.04$, this analysis would also challenge the primary conclusion. This is a correct and direct way to assess the impact of such biases.\n3.  **Missing Data:** It proposes a worst-case imputation for an adverse event: all missing outcomes for $T$ are events, and all for $C$ are non-events. This is the correct extreme scenario to create the largest possible risk difference and stress-test the finding. Complementing this with a tipping-point analysis is a hallmark of a rigorous approach.\n4.  **Consistency Check:** Verifying conclusions on a different scale (e.g., log risk ratio) is a good practice for ensuring robustness.\n\nThis plan is methodologically sound, rigorous, and directly addresses all the critical concerns.\n\n**Option B** is a collection of poor statistical practices. Switching the scale post hoc is inappropriate. Using only the per-protocol population invites selection bias. Last observation carried forward (LOCF) is a discredited imputation method. Ignoring uncertainty in the historical evidence leads to an anti-conservative, overly large margin, making it too easy to claim noninferiority.\n\n**Option C** is insufficient. A superiority test is irrelevant to the question of noninferiority when the new drug is directionally worse. Relying solely on multiple imputation under a single missing-at-random (MAR) assumption is not a robust sensitivity analysis; it fails to explore plausible scenarios where data are missing not at random (NMAR). Most importantly, it completely ignores the problem of constancy violation.\n\n**Option D** proposes abandoning the entire prespecified framework for a post hoc analysis using an external control group. This is not a sensitivity analysis; it is a new, likely biased analysis that introduces its own profound, untestable assumptions about the comparability of the external group.\n\nTherefore, Option A represents the most appropriate and rigorous sensitivity analysis plan. It uses a combination of standard, accepted methods to systematically challenge the primary conclusion from multiple angles.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}